Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.20
IPXL's Cash-to-Debt is ranked lower than
84% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. IPXL: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
IPXL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2  Med: 14.86 Max: No Debt
Current: 0.2
Equity-to-Asset 0.32
IPXL's Equity-to-Asset is ranked lower than
86% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. IPXL: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
IPXL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.54 Max: 0.84
Current: 0.32
0.2
0.84
Piotroski F-Score: 2
Altman Z-Score: 0.04
Beneish M-Score: -5.63
WACC vs ROIC
7.39%
-41.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -74.55
IPXL's Operating Margin % is ranked lower than
85% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. IPXL: -74.55 )
Ranked among companies with meaningful Operating Margin % only.
IPXL' s Operating Margin % Range Over the Past 10 Years
Min: -74.55  Med: 14.59 Max: 44.72
Current: -74.55
-74.55
44.72
Net Margin % -71.50
IPXL's Net Margin % is ranked lower than
85% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. IPXL: -71.50 )
Ranked among companies with meaningful Net Margin % only.
IPXL' s Net Margin % Range Over the Past 10 Years
Min: -71.5  Med: 11.2 Max: 46
Current: -71.5
-71.5
46
ROE % -66.49
IPXL's ROE % is ranked lower than
90% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. IPXL: -66.49 )
Ranked among companies with meaningful ROE % only.
IPXL' s ROE % Range Over the Past 10 Years
Min: -66.49  Med: 12.27 Max: 125.75
Current: -66.49
-66.49
125.75
ROA % -29.87
IPXL's ROA % is ranked lower than
85% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. IPXL: -29.87 )
Ranked among companies with meaningful ROA % only.
IPXL' s ROA % Range Over the Past 10 Years
Min: -29.87  Med: 7.63 Max: 38.8
Current: -29.87
-29.87
38.8
ROC (Joel Greenblatt) % -164.02
IPXL's ROC (Joel Greenblatt) % is ranked lower than
84% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.97 vs. IPXL: -164.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IPXL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -164.02  Med: 40.77 Max: 236.29
Current: -164.02
-164.02
236.29
3-Year Revenue Growth Rate 15.90
IPXL's 3-Year Revenue Growth Rate is ranked higher than
80% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. IPXL: 15.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IPXL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 30.1 Max: 204.1
Current: 15.9
0
204.1
GuruFocus has detected 3 Warning Signs with Impax Laboratories Inc $IPXL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IPXL's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:CSWYF, OTCPK:KHTRF, OTCPK:NPPNY, OTCPK:TWMJF, NAS:EGRX, NAS:SGYP, NAS:INNL, OTCPK:TZHGF, NYSE:DPLO, NAS:MNTA, NAS:AMPH, NAS:HRTX, NYSE:LCI, OTCPK:LPCUF, NAS:PAHC, NAS:DEPO, NAS:SCLN, OTCPK:APHQF, NAS:FLXN, OTCPK:ACBFF » details
Traded in other countries:ILR.Germany,
Headquarter Location:USA
Impax Laboratories Inc is a pharmaceutical company. It develops and commercializes brand-name pharmaceuticals.

Impax Laboratories makes generic drugs, specializing in controlled-release formulations of brand-name pharmaceuticals. Impax was formed through a recapitalization in 1999, with privately held Impax Pharmaceuticals merging into Global Pharmaceutical Corporation. Based in Hayward, Calif., the company employs about 750 people in 12 facilities in the United States and one under construction in Taiwan.

Top Ranked Articles about Impax Laboratories Inc

Impax to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
Impax to Present at the Bank of America Merrill Lynch Healthcare Conference
Impax Announces FDA Approval and Launch of a Generic Version of Vytorin® (Ezetimibe/Simvastatin Tablets)
Impax to Present Data on Rytary® (Carbidopa and Levodopa) Extended-Release Capsules, Zomig® (Zolmitriptan) Nasal Spray and Investigational Drug IPX203 at the 2017 American Academy of Neurology® Annual Meeting
Impax to Report First Quarter 2017 Results on May 10, 2017
Impax Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
Teva: Good Value, Questionable Management? Teva Pharmaceutical shares lost half their value in 2016
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Investor reports latest quarterly portfolio
Samuel Isaly (Trades, Portfolio), manager of the Eaton Vance Worldwide Health Care Fund (ETHSX), invested in three health care companies and eliminated his position in three others during the second quarter of 2016. An active health care investor, Isaly seeks long-term capital growth in health care companies that have potential for high growth and increased market share. The portfolio manager generally has 80% of his assets in health sciences industries, including biotechnology, pharmaceuticals and medical equipment. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 24.57
IPXL's Forward PE Ratio is ranked lower than
59% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.73 vs. IPXL: 24.57 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.27
IPXL's PB Ratio is ranked higher than
68% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. IPXL: 2.27 )
Ranked among companies with meaningful PB Ratio only.
IPXL' s PB Ratio Range Over the Past 10 Years
Min: 1.09  Med: 2.35 Max: 4.3
Current: 2.27
1.09
4.3
PS Ratio 1.46
IPXL's PS Ratio is ranked higher than
78% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. IPXL: 1.46 )
Ranked among companies with meaningful PS Ratio only.
IPXL' s PS Ratio Range Over the Past 10 Years
Min: 0.73  Med: 2.5 Max: 5.74
Current: 1.46
0.73
5.74
Price-to-Operating-Cash-Flow 33.59
IPXL's Price-to-Operating-Cash-Flow is ranked lower than
69% of the 284 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.79 vs. IPXL: 33.59 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IPXL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.84  Med: 14.2 Max: 2860
Current: 33.59
1.84
2860
Shiller PE Ratio 34.13
IPXL's Shiller PE Ratio is ranked higher than
66% of the 196 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.28 vs. IPXL: 34.13 )
Ranked among companies with meaningful Shiller PE Ratio only.
IPXL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.94  Med: 27.13 Max: 506.2
Current: 34.13
13.94
506.2
Current Ratio 1.74
IPXL's Current Ratio is ranked lower than
66% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. IPXL: 1.74 )
Ranked among companies with meaningful Current Ratio only.
IPXL' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 3.18 Max: 10.65
Current: 1.74
1.12
10.65
Quick Ratio 1.17
IPXL's Quick Ratio is ranked lower than
70% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. IPXL: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
IPXL' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 2.75 Max: 10.07
Current: 1.17
0.63
10.07
Days Inventory 59.14
IPXL's Days Inventory is ranked higher than
80% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.03 vs. IPXL: 59.14 )
Ranked among companies with meaningful Days Inventory only.
IPXL' s Days Inventory Range Over the Past 10 Years
Min: 50.25  Med: 87.54 Max: 118.81
Current: 59.14
50.25
118.81
Days Sales Outstanding 99.72
IPXL's Days Sales Outstanding is ranked lower than
68% of the 655 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. IPXL: 99.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPXL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.05  Med: 85.17 Max: 189.27
Current: 99.72
34.05
189.27
Days Payable 26.45
IPXL's Days Payable is ranked lower than
88% of the 603 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.27 vs. IPXL: 26.45 )
Ranked among companies with meaningful Days Payable only.
IPXL' s Days Payable Range Over the Past 10 Years
Min: 20.18  Med: 40.82 Max: 57.29
Current: 26.45
20.18
57.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.90
IPXL's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. IPXL: -1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPXL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -86.4  Med: -5 Max: -1.7
Current: -1.9
-86.4
-1.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.36
IPXL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. IPXL: 1.36 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IPXL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.31 Max: 3.44
Current: 1.36
0.61
3.44
Price-to-Median-PS-Value 0.60
IPXL's Price-to-Median-PS-Value is ranked higher than
92% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. IPXL: 0.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IPXL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.46  Med: 1.37 Max: 33.6
Current: 0.6
0.46
33.6
Earnings Yield (Greenblatt) % -31.36
IPXL's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.98 vs. IPXL: -31.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IPXL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -48.4  Med: 8.4 Max: 56
Current: -31.36
-48.4
56
Forward Rate of Return (Yacktman) % -1.03
IPXL's Forward Rate of Return (Yacktman) % is ranked lower than
71% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.09 vs. IPXL: -1.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IPXL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -21.3  Med: 2.9 Max: 86.1
Current: -1.03
-21.3
86.1

More Statistics

Revenue (TTM) (Mil) $783.32
EPS (TTM) $ -7.84
Beta1.13
Short Percentage of Float14.03%
52-Week Range $7.75 - 32.20
Shares Outstanding (Mil)73.70

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 797 855 887
EPS ($) 0.66 1.13 1.68
EPS without NRI ($) 0.66 1.13 1.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IPXL

Headlines

Articles On GuruFocus.com
Magna innovations help Lincoln redefine luxury on the 2017 Continental Jun 22 2017 
Kids Foot Locker Goes '1-ON-1' with Top NBA Draft Prospects Jun 22 2017 
Voya Financial Chosen as New Service Provider for Kern County, California, Retirement Plans Jun 22 2017 
AAM Recognizes Key Suppliers with Excellence Awards Jun 22 2017 
Turtle Beach Signs Worldwide Counter-Strike: Global Offensive Powerhouse - Astralis - To Multi-Year Jun 22 2017 
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Sky Solar Ho Jun 22 2017 
Capital One Financial Corporation to Webcast Conference Call on Second Quarter 2017 Earnings Jun 22 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors With Over $200k in Losses o Jun 22 2017 
Gartner Names CSRA to Global Top 100 in IT Jun 22 2017 
Twitter and Sela Sport Partner to Live Stream 2017 Arab Championship Matches Jun 22 2017 

More From Other Websites
Today's Research Reports on Stocks to Watch: Agenus and Impax Laboratories Jun 21 2017
Impax Laboratories, Inc. – Value Analysis (NASDAQ:IPXL) : June 16, 2017 Jun 16 2017
Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe Jun 16 2017
Impax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IPXL-US : June 15,... Jun 15 2017
Why Is Impax (IPXL) Down 2.4% Since the Last Earnings Report? Jun 14 2017
New FDA boss sends message on addictive opioids. Will this East Bay drug maker benefit? Jun 09 2017
Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER Jun 09 2017
How Endo's Opioid Pitfall Could Be A Boon For These Drugmakers Jun 09 2017
Endo's Pain Is Good For Collegium, Mixed For Impax Jun 09 2017
Who Wins From Endo’s Opana Getting Pulled From the Market Jun 09 2017
Impax to Present at the Goldman Sachs 38th Annual Global Healthcare Conference Jun 08 2017
Impax Laboratories Trying To Close In On Key Technical Benchmark Jun 02 2017
Impax to Present at the UBS Global Healthcare Conference May 17 2017
Edited Transcript of IPXL earnings conference call or presentation 10-May-17 12:30pm GMT May 16 2017
ETFs with exposure to Impax Laboratories, Inc. : May 15, 2017 May 15 2017
These Stocks Show Change of Direction May 15 2017
Impax Laboratories, Inc. :IPXL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan May 11 2017
Impax to Present at the Bank of America Merrill Lynch Healthcare Conference May 11 2017
Investor Network: Impax Laboratories, Inc. to Host Earnings Call May 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}